AI Terminal
BB Biotech AG
Earnings Release • Jul 12, 2018
833_rns_2018-07-12_ae87982a-feaa-41d5-96ca-2bd1ec961022.html
Earnings Release
Open in ViewerOpens in native device viewer
News Details
Ad-hoc | 12 July 2018 18:05
BB Biotech AG reports preliminary results for 1H 2018
BB BIOTECH AG / Key word(s): Profit Warning/Half Year Results
BB Biotech AG reports preliminary results for 1H 2018
12-Jul-2018 / 18:05 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Media Release, July 12, 2018
BB Biotech AG reports preliminary results for 1H 2018
In accordance with regulations on ad hoc publicity, BB Biotech AG (ISIN CH0038389992) is releasing the following information about its results for the first half year of 2018.
Based on preliminary unaudited consolidated results, BB Biotech closed the first half year of 2018 with a loss of around CHF 70 mn (CHF 478.4 mn profit in the corresponding period of the previous year). As an investment company, the result reflects the performance of the stocks it holds in its investment portfolio.
BB Biotech’s share price increased 8.4% in CHF and 8.2% in EUR during the corresponding period.
The interim report as of June 30, 2018 will be published on July 20, 2018.
For further information:
Investor Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 00
Dr. Silvia Schanz, [email protected]
Maria-Grazia Iten-Alderuccio, [email protected]
Claude Mikkelsen, [email protected]
Media Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 07
Tanja Chicherio, [email protected]
Company profile
BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world’s largest investors in this sector. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech’s investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.
12-Jul-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
| Language: | English |
| Company: | BB BIOTECH AG |
| Schwertstrasse 6 | |
| 8200 Schaffhausen | |
| Switzerland | |
| Phone: | +41 52 624 08 45 |
| E-mail: | [email protected] |
| Internet: | www.bbbiotech.ch |
| ISIN: | CH0038389992 |
| WKN: | A0NFN3 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart; SIX |
| End of Announcement | DGAP News Service |